Home > Axel Merseburger, ASCO20: Clinical Updates in Urothelial Carcinoma and Renal Cell Carcinoma
Genitourinary Cancers

Axel Merseburger, ASCO20: Clinical Updates in Urothelial Carcinoma and Renal Cell Carcinoma

Published Online: June 9th 2020

We are joined by touchONCOLOGY European Oncology & Haematology Editor-in-Chief Dr Axel S Merseburger to discuss his highlights from the JAVELIN Bladder 100 Trial (Clinicaltrials.gov identifier: NCT02603432) and the KEYNOTE-426 phase III trial in patients with clear cell renal cell carcinoma (ClinicalTrials.gov identifier: NCT02853331).

Questions

1. What are the current unmet needs in the treatment of urothelial carcinoma and how do you see the results of the Javelin Bladder 100 trial impacting the future in this clinical setting? (0:06)

2. What were the main take-home messages from the KEYNOTE-426 phase III trial in patients with clear cell renal cell carcinoma? (3:30)

 

Speaker disclosure: Axel S Merseburger has no financial or non-financial conflicts of interest in relation to this video.

Support: Interview and filming supported by Touch Medical Media.

Filmed in coverage of the 2020 ASCO Virtual Scientific Program.

Share this Video
Related Videos In Genitourinary Cancers
  • Copied to clipboard!
    accredited arrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greyarrow-right-orangearrow-right-whitearrow-right-blueavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-whiteticktimetranscriptup-arrowwebinar